Related Experiment Video
Updated: Jan 7, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Adjusting for covariates in randomized clinical trials for drugs and biological products
1Division of Biometrics IV, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Abstract:
In May 2023, the US Food and Drug Administration released a guidance document on adjusting for covariates in randomized clinical trials for drugs and biological products. This article provides a summary of motivations for the US Food and Drug Administration guidance document, recommendations in the guidance document, considerations for covariate adjustment in large trials and small trials, and additional topics beyond the scope of the guidance document that may benefit from greater consensus on best practices. A covariate-adjusted prespecified primary analysis can have advantages over an unadjusted analysis and is generally acceptable to the US Food and Drug Administration.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Blinding
Randomized Experiments
Simple randomization
Simple...
Dosage Regimen: Individualization